Cantor Fitzgerald Reiterates Overweight Rating, $95 Price Target on I-Mab (IMAB), Expects "Greater Appreciation for the Company's Pipeline"

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $95.00 price target on I-Mab (NASDAQ: IMAB).

The analyst comments: ""We are highlighting some recent developments in the competitor space for anti-CD47s and anti-CD73s that we believe provide positive read-throughs to IMAB's two pipeline assets that receive the most investor focus: lemzoparlimab/TJC4 (CD47 antibody) and uliledlimab/TJD5 (CD73 antibody). The news/updates support our OW rating and 12-month PT of $95 for IMAB shares. We continue to believe that IMAB is unique among China-based biotechs because it exclusively focuses on and is well-capitalized to deliver on the discovery, development, and commercialization of first-in-class and/or best-in-class drugs. We think a greater appreciation for the company’s pipeline will result in increased earnings estimates that should drive IMAB's stock higher."

For an analyst ratings summary and ratings history on I-Mab click here. For more ratings news on I-Mab click here.

Shares of I-Mab closed at $14.03 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Target (TGT) PT Raised to $146 at Piper Sandler
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August